Published in Curr Top Behav Neurosci on January 01, 2010
50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov (2013) 1.28
Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci (2011) 0.86
Dopaminergic and serotonergic drug use: a nationwide register-based study of over 1,300,000 older people. PLoS One (2011) 0.75
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci (2003) 2.37
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
Ambivalent reactions in the parent and offspring relationship. J Gerontol B Psychol Sci Soc Sci (2006) 2.04
Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci (2006) 2.01
A key role for orexin in panic anxiety. Nat Med (2009) 1.63
Studying actin-dependent processes in tissue culture. Nat Rev Mol Cell Biol (2002) 1.49
The health and housing in transition study: a longitudinal study of the health of homeless and vulnerably housed adults in three Canadian cities. Int J Public Health (2011) 1.39
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety (2010) 1.24
NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology (2011) 1.16
Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci (2002) 1.15
Blocking melanin-concentrating hormone MCH1 receptor affects rat sleep-wake architecture. Eur J Pharmacol (2007) 1.13
In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery. Prog Neurobiol (2010) 1.05
Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol (2004) 1.04
Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure. Neuropsychopharmacology (2011) 0.98
Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. J Med Chem (2013) 0.97
IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology (2007) 0.96
Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr Top Behav Neurosci (2010) 0.95
Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Bioorg Med Chem Lett (2012) 0.94
Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness. Eur J Pharmacol (2010) 0.93
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry (2005) 0.92
Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅). J Med Chem (2014) 0.92
The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders. Psychopharmacology (Berl) (2013) 0.91
Chronic corticosterone manipulations in mice affect brain cell proliferation rates, but only partly affect BDNF protein levels. Neurosci Lett (2005) 0.91
Cholinergic blockade impairs performance in operant DNMTP in two inbred strains of mice. Pharmacol Biochem Behav (2002) 0.90
A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses. Int J Neuropsychopharmacol (2010) 0.90
Decreased GABA levels in anterior cingulate cortex/medial prefrontal cortex in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.89
Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives. Psychopharmacology (Berl) (2013) 0.86
Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice. Brain Res Mol Brain Res (2004) 0.85
Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology (2006) 0.85
Transcriptional response to corticotropin-releasing factor in AtT-20 cells. Mol Pharmacol (2004) 0.85
Family psychopathology and magnitude of reductions in occipital cortex GABA levels in panic disorder. Neuropsychopharmacology (2004) 0.83
Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Drug Metab Dispos (2013) 0.82
Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold. Bioorg Med Chem Lett (2012) 0.82
Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol (2008) 0.82
Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv (2011) 0.82
Synaptic transmission changes in fear memory circuits underlie key features of an animal model of schizophrenia. Behav Brain Res (2011) 0.82
Increased resting-state functional connectivity between the anterior cingulate cortex and the precuneus in panic disorder: resting-state connectivity in panic disorder. J Affect Disord (2013) 0.81
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) (2009) 0.81
Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain. Mol Ther (2010) 0.81
Decreased expression of multidrug efflux transporters in the brains of GSK-3beta transgenic mice. Brain Res (2009) 0.80
Touching on translation. Cell Tissue Res (2013) 0.80
Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) (2010) 0.79
Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry (2013) 0.79
In vivo evidence for ligand-specific receptor activation in the central CRF system, as measured by local cerebral glucose utilization. Peptides (2009) 0.78
Stress-induced decreases in local cerebral glucose utilization in specific regions of the mouse brain. BMC Res Notes (2011) 0.77
A hierarchical Binomial-Poisson model for the analysis of a crossover design for correlated binary data when the number of trials is dose-dependent. J Biopharm Stat (2005) 0.77
R278995/CRA0450, a corticotropin-releasing factor (CRF(1)) receptor antagonist modulates REM sleep measures in rats: Implication for therapeutic indication. Eur J Pharmacol (2012) 0.76
Behavioral neurobiology of anxiety and its treatment. Preface. Curr Top Behav Neurosci (2010) 0.76
Early life stress and psychopharmacology. Psychopharmacology (Berl) (2011) 0.76
In the grey zone between epilepsy and schizophrenia: alterations in group II metabotropic glutamate receptors. Acta Neurol Belg (2014) 0.76
Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity. J Med Chem (2005) 0.76
Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism. Bioorg Med Chem (2007) 0.76
Accuracy of bedside ultrasound to assess cardiac function and volume status in critically ill trauma patients. J Trauma (2009) 0.75
4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives as non-peptidic selective delta-opioid agonists with potential anxiolytic/antidepressant properties. Part 2. Bioorg Med Chem Lett (2007) 0.75
Elizabeth Hay interviewed by Fiona Watt. J Cell Sci (2004) 0.75
Behavioral testing of antidepressant compounds: an analysis of crossover design for correlated binary data. Biom J (2005) 0.75
4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists. Bioorg Med Chem Lett (2005) 0.75
Interactions between CRF and acetylcholine in the modulation of cognitive behaviour. EXS (2006) 0.75
Dosing cards for treatment of children exposed to weapons of mass destruction. Am J Health Syst Pharm (2006) 0.75